HealthEquity Stock Price and Value Analysis

HealthEquity (NasdaqGS:HQY) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold HealthEquity to reach your target.

Target type

HQY Free Cash Flow Trend

Free Cash Flow trendline for HQY
Free Cash Flow trendline for HealthEquity
CSV

Based on historical returns, we believe that HealthEquity can grow its free cash at a rate of about 17%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is making money at a great rate!
  • This company is less known than others.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the HQY Numbers

HQY Price
(HealthEquity stock price per share)
$94.75
[?] HQY Fair Price
(based on intrinsic value)
$25.48
[?] HQY Safety Price (based on a variable margin of safety) $15.29
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 160% higher than other Industrials stocks
[?] PE Ratio versus Industry 0% lower than other Specialty Business Services stocks
[?] Free Cash Flow Jitter 41%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 5,475,425 shares shorted. With 80,970,003 shares available for purchase and an average trading volume over the past 10 trading days of 750,230, it would take at least 7.3 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2012 1428336 10.9
2013 1428336 16.8
2014 1428336 13.7
2015 1428336 24.9
2016 1428336 43.6
2017 1428336 78.7
2018 1428336 110
2019 1428336 100
2020 1428336 175
2021 1428336 133
2022 1428336 143
2023 1428336 236
2024 1428336 334
2025 1428336 453

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 12 fiscal years from 2012 to 2025 with positive net income, operating cash flow totaled $1,638 million against net income of $603 million, or 2.72 times. Net income was negative in 2 of the 14 years, and those years are left out of the ratio.

In 2025, operating cash flow was 2.12 times net income, compared with 1.99 times for the earliest three years (2012 to 2014).

In 2025, capital expenditures were $2 million, 0.4% of operating cash flow of $457 million, which leaves an estimated $455 million after capex. Across the 14 years with reported capex, it averaged 3.0% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2012 11.2 11.8 0.8 1.05
2013 1.2 18 1.6 14.61
2014 10.2 15 1.7 1.48
2015 16.6 26.5 2.4 1.60
2016 26.4 45.6 3.6 1.73
2017 47.4 81.7 5.5 1.73
2018 73.9 113 3.9 1.53
2019 39.7 105 7.3 2.65
2020 8.8 182 13.1 20.56
2021 -44.3 141 8.9 n/a
2022 -26.1 151 3.4 n/a
2023 55.7 243 1.7 4.36
2024 96.7 340 2.1 3.51
2025 215 457 2 2.12

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 4 fiscal years from 2013 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $818 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 2 of those years with dividend payment facts, dividends paid totaled $51 million, 167.5% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 1 of those 2 years.

In 3 of the 4 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $424 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, cash spent repurchasing shares was $299 million, 66.0% of estimated free cash flow of $453 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2013 16.8 0.7 3.4 4.1 24.4%
2014 13.7 50.3 n/a 50.3 368.4%
2024 334 n/a 121 121 36.4%
2025 453 n/a 299 299 66.0%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $46.1 million in 2012 and $1,313 million in 2025, a compound annual growth rate of 29.4% over 13 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.

Revenue rose 9.5% from 2024 to 2025.

Our estimated free cash flow was $453 million in 2025, 34.5% of revenue. In 2012 the estimated margin was 23.7%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2012 46.1 10.9 23.7%
2013 62 16.8 27.1%
2014 87.9 13.7 15.6%
2015 127 24.9 19.6%
2016 178 43.6 24.4%
2017 230 78.7 34.3%
2018 287 110 38.3%
2019 532 100 18.9%
2020 734 175 23.8%
2021 757 133 17.6%
2022 862 143 16.6%
2023 1,000 236 23.6%
2024 1,200 334 27.8%
2025 1,313 453 34.5%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $319 million against total liabilities of $1,273 million, or 25.1% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 37.7% of total assets in 2025, compared with 123.1% in 2013, a decrease of 85.4 percentage points.

Stockholders equity was $2,107 million in 2025, up from negative equity of -$12.7 million in 2013.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 15.6% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2013 55.1 13.9 67.8 -12.7
2014 159 111 14.7 144
2015 220 83.6 16.3 203
2016 279 140 17.2 262
2017 369 199 22.9 346
2018 510 361 32.9 477
2019 2,565 192 1,535 1,030
2020 2,710 329 1,332 1,379
2021 3,107 225 1,255 1,853
2022 3,089 254 1,193 1,896
2023 3,164 404 1,129 2,035
2024 3,449 296 1,334 2,115
2025 3,380 319 1,273 2,107

Price Versus Our Estimated Value

Every one of the 14 fiscal years we have for HealthEquity under its current filer shows positive free cash flow.

At $94.75, HealthEquity trades above our fair value estimate of $25.48.

Free cash flow from the first three years of data averaged $13.8 million, and from the last three $341 million: a sharp rise.

Year-to-year variability in free cash flow is volatile, measured at 41%.

No dividend yield is recorded for HealthEquity in our data.

Our value investing guide explains how to test these numbers against the filings themselves.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 160% above the average for stocks in the Industrials sector.

Its trailing P/E ratio is in line with the average for stocks in the Specialty Business Services industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Specialty Business Services industry, the ones closest in market capitalization to HealthEquity, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
HealthEquity (HQY) 7,837 34.2 - - 272% above
ExlService Holdings (EXLS) 6,291 25.0 - 1.6% 74% above
Zillow Group (ZG) 6,218 - - - 77% below
Zillow Group (Z) 6,154 - - 0.5% 8% below
WEX (WEX) 5,750 15.1 - 1.6% 120% above
CoStar Group (CSGP) 11,913 68.9 - 1.5% 4% above
Akamai Technologies (AKAM) 12,275 33.1 - 6.1% 47% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1428336.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: HQY annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in HQY

Does HealthEquity have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: HQY

This example shows how we apply the Trendshare checklist to HQY: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 94.75
    • Market cap: $7.8B
    • EPS: 2.77
  2. Step 2 — Valuation checks

    • P/E: 34.206
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.